grant
EPIC-LT: Eliminating PGD through Inhibition of CCR5 in Lung Transplantation
Organization UNIVERSITY OF CALIFORNIA, SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 1 Aug 2025Deadline 31 Jul 2028
NIHUS FederalResearch GrantFY2025ARDSAcute Respiratory DistressAcute Respiratory Distress SyndromeAdult ARDSAdult RDSAdult Respiratory Distress SyndromeAdverse ExperienceAdverse eventAllograftingAssayAwarenessBioassayBiologicalBiological AssayBiological MarkersBlood PlasmaBody TissuesBronchioalveolar LavageBronchoalveolar LavageBronchopulmonary LavageC-C CKR-5C-C CKR-5 GeneC-C Chemokine Receptor Type 5C-C Chemokine Receptor Type 5 GeneCC Chemokine Receptor 5CC-CKR-5CC-CKR-5 GeneCC-CKR5CCCKR5CCCKR5 GeneCCL5CCR-5CCR-5 GeneCCR5CCR5 ProteinCCR5 ReceptorsCCR5 geneCD195 AntigenCD195 Antigen GeneCHEMR13CHEMR13 GeneCKR-5CKR-5 GeneCKR5CKR5 GeneCKR5 ReceptorsCMKBR5CMKBR5 GeneCause of DeathCell BodyCellsCessation of lifeChemokine (C-C Motif) Ligand 5Chemokine (C-C Motif) Receptor 5Chemokine (C-C) Receptor 5Chemokine (C-C) Receptor 5 GeneChemokine Receptor GeneChronicClinicalClinical TrialsCollectionComplementComplement ProteinsConsentCystic FibrosisCytotoxic cellD17S136EDa Nang LungDataDeathDiseaseDisorderDoseDrug InteractionsDrugsDysfunctionELISAEnzyme GeneEnzyme-Linked Immunosorbent AssayEnzymesEventFDA approvedFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFoundationsFunctional disorderFutureHIV-1 Fusion Co-ReceptorHIV-1 Fusion Co-Receptor GeneHumanImmuneImmunesImmunosuppressionImmunosuppression EffectImmunosuppressive EffectIncidenceInfectionInjuryInnate Immune ResponseIntensive Care UnitsInterventionIschemia-Reperfusion InjuryK lymphocyteLength of StayLigandsLungLung GraftingLung LavageLung Respiratory SystemLung TransplantationLung damageMGC17164Mass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMeasuresMediatorMedicalMedicationModern ManMonitorMucoviscidosisMulti-Institutional Clinical TrialMulti-center clinical trialMulti-center trialMulti-site clinical trialMulticenter TrialsMulticenter clinical trialMultisite clinical trialNK CellsNational Institutes of HealthNatural Killer CellsNumber of Days in HospitalOrganOrgan PreservationParticipantPathogenesisPatient CarePatient Care DeliveryPatientsPerioperativePharmaceutical PreparationsPhasePhenotypePhysiopathologyPilot ProjectsPlacebosPlasmaPlasma SerumPopulationPostoperativePostoperative PeriodPredicting RiskPreventionProcessProphylactic treatmentProphylaxisProtocolProtocols documentationPulmonary GraftPulmonary TransplantPulmonary TransplantationQOLQuality of lifeRANTESRandomizedReference RangesReference ValuesRegimenRenal functionReperfusion DamageReperfusion InjuryResearch DesignReticuloendothelial System, Serum, PlasmaRiskRisk FactorsRoleSCYA5SIS deltaSIS-deltaSISdSafetySample SizeSamplingSeveritiesSham TreatmentShock LungSiteSmall Inducible Cytokine A5SolidStiff lungStudy TypeSurrogate MarkersT-Cell RANTES ProteinT-Cell Specific Protein p288TCP228TacrolimusTestingTherapeuticTherapeutic FungicidesTimeTissuesTransplant RecipientsTransplantationUnited States National Institutes of HealthVentilatorWaiting Listsacceptability and feasibilityanti-fungalanti-fungal agentsanti-fungal drugbio-markersbiobankbiologicbiologic markerbiomarkerbiorepositorybronchiolar alveolar lavagebronchopulmonary lavage therapycare for patientscare of patientscaring for patientschemokine receptorclinical phenotypecomplementationcytokinedrug/agentenzyme linked immunoassayflow cytophotometryforecasting riskgraft dysfunctiongraft failurehospital dayshospital length of stayhospital stayimmune suppressionimmune suppressive activityimmune suppressive functionimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimprovedinfection riskinhibitorinjuriesinstrumentintervention armkidney functionlung allograftlung functionlung injurylung transplantmortalitymouse modelmurine modelnew approachesnovelnovel approachesnovel strategiesnovel strategypathophysiologypilot studypilot trialpredict riskpredict riskspredicted riskpredicted riskspredicting riskspredictive riskpredicts riskpreventpreventingpulmonary damagepulmonary functionpulmonary injurypulmonary tissue damagepulmonary tissue injuryrandomisationrandomizationrandomly assignedrecruitrisk predictionrisk predictionssafety assessmentsham therapyside effectsocial rolestudy designstudy populationsuccesssurrogate bio-markerssurrogate biomarkerstargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttooltransplanttransplant patienttreatment armwaitlistwet lung
Description preview
Project Summary
Lung transplant recipient survival lags other solid organ recipients, with the main early causes of death being
primary graft dysfunction (PGD). PGD occurs in up to 1/3 of all recipients, is driven by the innate immune
response, and has no known medical therapies for treatment or prevention. Our group has recently shown that…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click